{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:44:48Z","timestamp":1786985088601,"version":"build-2736575974"},"reference-count":93,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.beem.2019.101366","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T19:47:29Z","timestamp":1574884049000},"page":"101366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Novel therapies for thyroid autoimmune diseases: An update"],"prefix":"10.1016","volume":"34","author":[{"given":"Silvia Martina","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poupak","family":"Fallahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Camastra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Rosaria","family":"Paparo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Gonnella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Ruffilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2019.101366_bib1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2014.10.016","article-title":"Autoimmune thyroid disorders","volume":"14","author":"Antonelli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2019.101366_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1398-9995.1998.tb04951.x","article-title":"The Th1\/Th2 paradigm and allergic disorders","volume":"53","author":"Romagnani","year":"1998","journal-title":"Allergy"},{"key":"10.1016\/j.beem.2019.101366_bib3","article-title":"Thyroid autoimmune disorders and cancer","author":"Ferrari","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.beem.2019.101366_bib4","doi-asserted-by":"crossref","first-page":"124","DOI":"10.2174\/1872214808666140723111533","article-title":"Cognitive function and quality of life in mild thyroid hormone deficiency","volume":"8","author":"Tognini","year":"2014","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"10.1016\/j.beem.2019.101366_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.beem.2011.11.001","article-title":"Quality of life in Graves' ophthalmopathy","volume":"26","author":"Wiersinga","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"key":"10.1016\/j.beem.2019.101366_bib6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","article-title":"Graves' ophthalmopathy","volume":"363","author":"Bahn","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.101366_bib7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/BF03346614","article-title":"Pathogenesis of Graves' orbitopathy: a 2010 update","volume":"33","author":"Smith","year":"2010","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2019.101366_bib8","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.2147\/OPTH.S67098","article-title":"Thyroid-stimulating immunoglobulins as measured in a reporter bioassay are not detected in patients with Hashimoto's thyroiditis and ophthalmopathy or isolated upper eyelid retraction","volume":"8","author":"Wall","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.beem.2019.101366_bib9","first-page":"417","article-title":"Pathogenesis of thyroid-associated ophthalmopathy: does autoimmunity against calsequestrin and collagen XIII play a role?","volume":"4","author":"Lahooti","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.beem.2019.101366_bib10","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1210\/jc.2002-021845","article-title":"Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up","volume":"88","author":"Dittmar","year":"2003","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101366_bib11","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.autrev.2016.09.009","article-title":"The association of other autoimmune diseases in patients with autoimmune thyroiditis: review of the literature and report of a large series of patients","volume":"15","author":"Fallahi","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2019.101366_bib12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.autrev.2018.10.001","article-title":"The association of other autoimmune diseases in patients with Graves' disease (with or without ophthalmopathy): review of the literature and report of a large series","volume":"18","author":"Ferrari","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2019.101366_bib13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1530\/ERC-11-0028","article-title":"Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine","volume":"18","author":"Fiore","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.beem.2019.101366_bib14","first-page":"313","article-title":"Both thyroid autoimmunity and increased serum TSH are independent risk factors for malignancy in patients with thyroid nodules","volume":"36","author":"Boi","year":"2013","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2019.101366_bib15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2265.2011.04318.x","article-title":"Twin studies as a model for exploring the aetiology of autoimmune thyroid disease","volume":"76","author":"Brix","year":"2012","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2019.101366_bib16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrendo.2013.56","article-title":"GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis","volume":"9","author":"Simmonds","year":"2013","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.beem.2019.101366_bib17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40618-014-0083-8","article-title":"Serum-negative autoimmune thyroiditis: what's in a name?","volume":"37","author":"Rotondi","year":"2014","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2019.101366_bib18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/RHU.0b013e3181d52a28","article-title":"Autoimmune thyroid disease and Sj\u00f6gren syndrome","volume":"16","author":"Alfaris","year":"2010","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.beem.2019.101366_bib19","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1002\/art.21413","article-title":"Linkage at 5q14.3-15 in multiplex systemic lupus erythematosus pedigrees stratified by autoimmune thyroid disease","volume":"52","author":"Namjou","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.beem.2019.101366_bib20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fendo.2017.00050","article-title":"Environmental issues in thyroid diseases","volume":"8","author":"Ferrari","year":"2017","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2019.101366_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.autrev.2016.01.001","article-title":"Smoke and autoimmunity: the fire behind the disease","volume":"15","author":"Perricone","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2019.101366_bib22","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/j.1365-2265.2012.04455.x","article-title":"Smoking cessation is followed by a sharp but transient rise in the incidence of overt autoimmune hypothyroidism - a population-based case-control study","volume":"77","author":"Carl\u00e9","year":"2012","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2019.101366_bib23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/cen.12066","article-title":"Selenium and the thyroid gland: more good news for clinicians","volume":"78","author":"Drutel","year":"2013","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2019.101366_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1743-422X-6-5","article-title":"Viruses and thyroiditis: an update","volume":"6","author":"Desailloud","year":"2009","journal-title":"Virol J"},{"key":"10.1016\/j.beem.2019.101366_bib25","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.297.18.2010","article-title":"Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus","volume":"297","author":"Giordano","year":"2007","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.beem.2019.101366_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2265.2007.03009.x","article-title":"Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection","volume":"68","author":"Indolfi","year":"2008","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2019.101366_bib27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.cyto.2008.01.002","article-title":"High values of CXCL10 serum levels in patients with hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune thyroiditis","volume":"42","author":"Antonelli","year":"2008","journal-title":"Cytokine"},{"key":"10.1016\/j.beem.2019.101366_bib28","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1089\/thy.2012.0507","article-title":"Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of hepatitis C virus and thyroiditis","volume":"23","author":"Blackard","year":"2013","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2019.101366_bib29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF03346699","article-title":"Environmental triggers of thyroiditis: hepatitis C and interferon-\u03b1","volume":"34","author":"Menconi","year":"2011","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.beem.2019.101366_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001639","article-title":"Lower serum 25-hydroxyvitamin D level is associated with 3 types of autoimmune thyroid diseases","volume":"94","author":"Ma","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.beem.2019.101366_bib31","first-page":"100196","article-title":"Chemokines in hyperthyroidism","volume":"16","author":"Ferrari","year":"2019","journal-title":"J\u00a0Clin Transl Endocrinol"},{"key":"10.1016\/j.beem.2019.101366_bib32","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20021897","article-title":"An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4","volume":"197","author":"Lasagni","year":"2003","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.beem.2019.101366_bib33","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2019.101366_bib34","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.cyto.2011.04.022","article-title":"Circulating chemokine (CXC motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association with CXCL10","volume":"55","author":"Antonelli","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.beem.2019.101366_bib35","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1210\/jc.2010-2905","article-title":"Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis","volume":"96","author":"Antonelli","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101366_bib36","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2265.2006.02447.x","article-title":"Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy","volume":"64","author":"Antonelli","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2019.101366_bib37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cytogfr.2014.01.006","article-title":"CXCR3, CXCL10 and type 1 diabetes","volume":"25","author":"Antonelli","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.beem.2019.101366_bib38","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1210\/jc.2005-1689","article-title":"Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"91","author":"Antonelli","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101366_bib39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1465-9921-14-121","article-title":"Interferoninducible chemokines reflect severity and progression in sarcoidosis","volume":"14","author":"Su","year":"2013","journal-title":"Respir Res"},{"key":"10.1016\/j.beem.2019.101366_bib40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1749-6632.2009.04813.x","article-title":"CXCR3, inflammation, and autoimmune diseases","volume":"1173","author":"Lacotte","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.beem.2019.101366_bib41","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.autrev.2012.10.001","article-title":"The interaction between CXCL10 and cytokines in chronic inflammatory arthritis","volume":"12","author":"Lee","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2019.101366_bib42","first-page":"1809","article-title":"Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis","volume":"35","author":"Antonelli","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.beem.2019.101366_bib43","first-page":"22","article-title":"High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthritis","volume":"27","author":"Antonelli","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.beem.2019.101366_bib44","doi-asserted-by":"crossref","first-page":"468107","DOI":"10.1155\/2012\/468107","article-title":"Cytokines and HCV-related disorders","volume":"2012","author":"Fallahi","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.beem.2019.101366_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1586\/1744666X.2015.997214","article-title":"Virus-driven autoimmunity and lymphoproliferation: the example of HCV infection","volume":"11","author":"Zignego","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.beem.2019.101366_bib46","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4254\/wjh.v7.i3.327","article-title":"Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin\u2019s lymphoma, and cancer","volume":"7","author":"Ferri","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.beem.2019.101366_bib47","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cyto.2019.01.003","article-title":"Immunological aspects of autoimmune thyroid disease - complex interplay between cells and cytokines","volume":"116","author":"Luty","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.beem.2019.101366_bib48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.yexmp.2004.08.004","article-title":"Early chemokine expression induced by interferon-gamma in a murine model of Hashimoto's thyroiditis","volume":"77","author":"Kimura","year":"2004","journal-title":"Exp Mol Pathol"},{"key":"10.1016\/j.beem.2019.101366_bib49","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/icb.2010.158","article-title":"CXCR3 ligands: redundant, collaborative and antagonistic functions","volume":"89","author":"Groom","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.beem.2019.101366_bib50","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.autrev.2010.08.018","article-title":"Bioassays for TSH-receptor autoantibodies: an update","volume":"10","author":"Lytton","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2019.101366_bib51","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0002-9440(10)64171-5","article-title":"Expression of IP-10\/CXCL10 and MIG\/CXCL9 in the thyroid and increased levels of IP-10\/CXCL10 in the serum of patients with recent-onset Graves' disease","volume":"161","author":"Romagnani","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.beem.2019.101366_bib52","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1530\/EJE-07-0019","volume":"156","author":"Inukai","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2019.101366_bib53","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1210\/jc.2006-1571","article-title":"Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter","volume":"92","author":"Antonelli","year":"2007","journal-title":"The journal of clinical endocrinology and metabolim"},{"key":"10.1016\/j.beem.2019.101366_bib54","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/thy.2009.0222","article-title":"A\u00a0CXC motif ligand 10 polymorphism as a marker to predict severity of Graves' disease","volume":"20","author":"Br\u00fcck","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2019.101366_bib55","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/thy.2009.0179","article-title":"Serum chemokine (C-X-C motif) ligand 10 levels are elevated in patients with Graves' disease in long-term remission","volume":"20","author":"Sakai","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2019.101366_bib56","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41433-018-0279-9","article-title":"The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy","volume":"33","author":"Huang","year":"2019","journal-title":"Eye"},{"key":"10.1016\/j.beem.2019.101366_bib57","first-page":"911","article-title":"CD4+ T cells and the Th1\/Th2 imbalance are implicated in the pathogenesis of Graves' ophthalmopathy","volume":"17","author":"Xia","year":"2006","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.beem.2019.101366_bib58","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1167\/iovs.05-0605","article-title":"Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy","volume":"46","author":"Feldon","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.beem.2019.101366_bib59","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1055\/s-0032-1316352","article-title":"Circulating CXCL9 and CXCL10 as markers of activity of Graves' orbitopathy during treatment with corticosteroids and teleradiotherapy","volume":"44","author":"Mysliwiec","year":"2012","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.beem.2019.101366_bib60","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1210\/jc.2013-3919","article-title":"A\u00a0prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with Graves' ophthalmopathy","volume":"99","author":"Zhu","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101366_bib61","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.metabol.2010.02.002","article-title":"Cytokines (interferon-\u03b3 and tumor necrosis factor-\u03b1)-induced nuclear factor-\u03baB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone","volume":"60","author":"Antonelli","year":"2011","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.beem.2019.101366_bib62","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3892\/mmr.2013.1714","article-title":"Role of PPARs in inflammatory processes associated with metabolic syndrome (Review)","volume":"8","author":"Fuentes","year":"2013","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.beem.2019.101366_bib63","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.MIB.0000160770.94199.9b","article-title":"Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms","volume":"11","author":"Schaefer","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.beem.2019.101366_bib64","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2007.03.113","article-title":"Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10 deficient mice","volume":"133","author":"Lee","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.beem.2019.101366_bib65","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.autrev.2014.08.025","article-title":"Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete \u03b1 (CXCL10) and \u03b2 (CCL2) chemokines under the influence of cytokines that are modulated by PPAR\u03b3","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2019.101366_bib66","doi-asserted-by":"crossref","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","article-title":"Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1","volume":"274","author":"Delerive","year":"1999","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beem.2019.101366_bib67","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1677\/JOE-07-0240","article-title":"Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes","volume":"195","author":"Crescioli","year":"2007","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.beem.2019.101366_bib68","first-page":"13","article-title":"High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy","volume":"126","author":"Antonelli","year":"1992","journal-title":"Acta Endocrinol"},{"key":"10.1016\/j.beem.2019.101366_bib69","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101366_bib70","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1586\/17512433.2016.1157468","article-title":"Novel therapies for thyroid autoimmune diseases","volume":"9","author":"Fallahi","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.beem.2019.101366_bib71","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1089\/thy.2011.2108.ed","article-title":"When will thyrotropin receptor antagonists and inverse thyrotropin receptor agonists become available for clinical use?","volume":"21","author":"Emerson","year":"2011","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2019.101366_bib72","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1210\/jc.2013-1149","article-title":"A\u00a0small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy","volume":"98","author":"Turcu","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101366_bib73","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s40265-014-0258-9","article-title":"Etanercept: a review of its use in autoimmune inflammatory diseases","volume":"74","author":"Scott","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.beem.2019.101366_bib74","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/sj.eye.6701768","article-title":"The effect of etanercept on Graves' ophthalmopathy: a pilot study","volume":"19","author":"Paridaens","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.beem.2019.101366_bib75","first-page":"2976","article-title":"Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease","volume":"81","author":"Salvi","year":"1996","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101366_bib76","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Annals of the rheumatic disease"},{"key":"10.1016\/j.beem.2019.101366_bib77","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2019.101366_bib78","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","article-title":"Treatment of active corticosteroid-resistant graves' orbitopathy","volume":"30","author":"P\u00e9rez-Moreiras","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"10.1016\/j.beem.2019.101366_bib79","first-page":"1","article-title":"Tocilizumab for the management of corticosteroid-resistant mild to severe graves' ophthalmopathy, a report of three cases","author":"Maldiney","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.beem.2019.101366_bib80","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1073\/pnas.0800555105","article-title":"Maintenance of the plasma cell pool is independent of memory B cells","volume":"105","author":"Ahuja","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.beem.2019.101366_bib81","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","article-title":"Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature","volume":"14","author":"Giuggioli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.beem.2019.101366_bib82","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/archopthalmol.2011.1215","article-title":"A\u00a0small dose of rituximab for graves orbitopathy: new insights into the mechanism of action","volume":"130","author":"Salvi","year":"2012","journal-title":"Archivies ophthalmol"},{"key":"10.1016\/j.beem.2019.101366_bib83","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves' orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101366_bib84","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101366_bib85","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/phar.2111","article-title":"Efficacy and safety of rituximab for the treatment of graves' orbitopathy: a meta-analysis of randomized controlled trials","volume":"38","author":"Shen","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.beem.2019.101366_bib86","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1080\/09273948.2018.1453078","article-title":"Low-dose rituximab for active moderate to severe graves' orbitopathy resistant to conventional treatment","volume":"27","author":"Du Pasquier-Fediaevsky","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.beem.2019.101366_bib87","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/cen.13970","article-title":"Early low-dose rituximab for active thyroid eye disease: an effective and well-tolerated treatment","volume":"91","author":"Insull","year":"2019","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.beem.2019.101366_bib88","article-title":"The effects of Rituximab on Graves'orbitopathy: a retrospective study of 14 patients","author":"Eid","year":"2019","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.beem.2019.101366_bib89","doi-asserted-by":"crossref","first-page":"E1635","DOI":"10.1210\/jc.2014-1580","article-title":"Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes","volume":"99","author":"Chen","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2019.101366_bib90","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2019.101366_bib91","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1089\/thy.2019.0036","article-title":"Antigen-specific immunotherapy with thyrotropin receptor peptides in graves' hyperthyroidism: a phase I study","volume":"29","author":"Pearce","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2019.101366_bib92","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1055\/a-0725-9297","article-title":"Reflections on thyroid autoimmunity: a personal overview from the past into the future","volume":"50","author":"Rapoport","year":"2018","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.beem.2019.101366_bib93","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.2741\/4688","article-title":"Antigen-specific therapy of Graves' disease and orbitopathy by induction of tolerance","volume":"23","author":"Ungerer","year":"2018","journal-title":"Front Biosci"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X19301174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X19301174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:55:05Z","timestamp":1761497705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X19301174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":93,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1521690X19301174"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2019.101366","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapies for thyroid autoimmune diseases: An update","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2019.101366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101366"}}